New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:18 EDTMSMorgan Stanley reports Q4 Basel 1 Tier 1 capital ratio 15.7%
Reports Q4 Basel 1 Tier 1 common equity ratio 12.8%. Reports Q4 investment banking revenue $1.56B, institutional securities revenue $3.33B, asset management revenue $2.5B, sales and trading revenue $1.6B, fixed income commodities sales and trading revenue $694M. James P. Gorman, Chairman and CEO, said, “Our Q4 results demonstrated the consistency embedded in our business model, as revenues increased year-over-year in all three of our business segments. Importantly, we are continuing to address many of the legal issues from the financial crisis. We look forward to further progress on our strategic goals as we move into 2014 with strength and momentum.”
News For MS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
06:57 EDTMSMorgan Stanley picked by GE as adviser for Japan leasing sale, Bloomberg reports
Subscribe for More Information
May 27, 2015
06:57 EDTMSAbbVie enters into ASR with Morgan Stanley to repurchase $5B of stock
AbbVie (ABBV) said in a regulatory filing that on May 26, it entered into an accelerated share repurchase agreement with Morgan Stanley (MS) to repurchase $5B of AbbVie’s common stock. Morgan Stanley is expected to make an initial delivery of approximately 68 million shares of AbbVie’s common stock on May 27, which represents 90% of the prepayment amount divided by the closing price of AbbVie’s common stock on May 26. At settlement of the agreement, Morgan Stanley may be required to deliver additional shares of AbbVie’s common stock to AbbVie or, under certain circumstances, AbbVie may be required to deliver shares of its common stock or may elect to make a cash payment to Morgan Stanley. The total number of shares of AbbVie’s common stock to be repurchased under the agreement will be based on the daily volume-weighted average price of AbbVie’s common stock during the term of the transaction, less a discount and subject to adjustment pursuant to the terms of the agreement. The final settlement of the transactions under the agreement is expected to occur before the end of 4Q15 and may be accelerated at the option of Morgan Stanley.This agreement was entered into pursuant to AbbVie’s previously disclosed share repurchase authorization and in connection with AbbVie’s previously announced acquisition of Pharmacyclics, which was completed on May 26.
May 20, 2015
08:21 EDTMSATM data theft soars to highest rate in two decades, WSJ says
Subscribe for More Information
06:10 EDTMSMorgan Stanley implied volatility of 16 at lower end of index mean range
Subscribe for More Information
May 18, 2015
09:46 EDTMSMPLX enters common unit sales agreement for up to $500M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use